CDX
NCI-H1373
Tumor indication
Lung
Tumor subtype
Lung adenocarcinoma
Description
NCI-H1373 (Lung Cancer CDX Model)
The NCI-H1373 cell line was derived from a non-small cell lung carcinoma (NSCLC). It carries a KRAS mutation, representing a frequent driver of NSCLC progression. The model provides reproducible tumor growth in xenografts. Its defined mutation status makes it highly relevant for targeted therapy research.
Key Features:
- Derived from non-small cell lung carcinoma.
- KRAS-mutant NSCLC model.
- Epithelial morphology.
- Tumorigenic in xenografts.
Applications:
NCI-H1373 is used in drug discovery for KRAS-driven NSCLC. Researchers apply it in targeted therapy and biomarker validation studies. It supports resistance mechanism evaluation in lung cancer. Its reproducibility makes it a valuable tool in translational oncology pipelines.
Details
- Tumor indication
- Lung
- Tumor subtype
- Lung adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.